Can Fite Biofarma (XTAE:CANF) 3-Year EPS without NRI Growth Rate : 37.30% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma 3-Year EPS without NRI Growth Rate?

Can Fite Biofarma's EPS without NRI for the three months ended in Dec. 2023 was ₪-0.02.

During the past 3 years, the average EPS without NRI Growth Rate was 37.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 46.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 33.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Can Fite Biofarma was 58.70% per year. The lowest was -12.90% per year. And the median was 23.60% per year.

Competitive Comparison of Can Fite Biofarma's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Can Fite Biofarma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's 3-Year EPS without NRI Growth Rate falls into.

Can Fite Biofarma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Can Fite Biofarma (XTAE:CANF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Can Fite Biofarma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (XTAE:CANF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

CANF:USA

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).